A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient
Authors:
Top Cited Papers
- 1 July 2004
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 127 (1) , 294-299
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABLCell, 2003
- PDGFRA Activating Mutations in Gastrointestinal Stromal TumorsScience, 2003
- Management of malignant gastrointestinal stromal tumoursThe Lancet Oncology, 2002
- Molecular Targeting of Platelet-Derived Growth Factor B by Imatinib Mesylate in a Patient With Metastatic Dermatofibrosarcoma ProtuberansJournal of Clinical Oncology, 2002
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberansInternational Journal of Cancer, 2002
- Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspectiveLeukemia, 2002
- Inhibition of KIT Tyrosine Kinase Activity: A Novel Molecular Approach to the Treatment of KIT-Positive MalignanciesJournal of Clinical Oncology, 2002
- STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implicationsOncogene, 2001
- Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosisVirchows Archiv, 2001